QCG
RDHL

Quadrant Capital Group’s Redhill Biopharma RDHL Stock Holding History

Quadrant Capital Group’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed -$13K – 2620
2021
Q2 		$13K Buy
+2
New +$13.8K ﹤0.01% 1445
2021
Q1 		– Hold
0
– – – 2276
2020
Q4 		– Hold
0
– – – 1989
2020
Q3 		– Hold
0
– – – 2039

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quadrant Capital Group's RDHL Position: Q3 2021 in Review

Quadrant Capital Group sold out of Redhill Biopharma (RDHL) in Q3 2021, closing a stake of 2 shares — an estimated $13K sold.

Quadrant Capital Group first reported a position in RDHL in Q2 2021 and held it in 1 quarter. The position peaked at $13K in Q2 2021. 53 funds tracked by Wall St. Rank hold RDHL as of Q3 2021.

  • Quadrant Capital Group reported no remaining Redhill Biopharma position as of Q3 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 2 Redhill Biopharma shares in Q3 2021, an estimated $13K.
  • Quadrant Capital Group first reported a position in Redhill Biopharma in Q2 2021 and held it in 1 quarter.
  • Quadrant Capital Group's Redhill Biopharma position peaked at $13K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2021.

Based on Quadrant Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.